Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA)

International Journal of Antimicrobial Agents

Volumn 37, Issue 6, 2011, Pages 558-561

  Leonard, Steven N ^a,b   Szeto, Yong G ^a   Zolotarev, Maria ^a   Grigoryan, Ilona V ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

hGISA; Inoculum effect; MRSA; Pneumonia

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; OXACILLIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 79955485246     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.02.007     Document Type: Article

References (16)

1. M.J. Rybak, S.N. Leonard, K.L. Rossi, C.M. Cheung, H.S. Sader, and R.N. Jones Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007) J Clin Microbiol 46 2008 2950 2954
2. Y. Maor, M. Hagin, N. Belausov, N. Keller, D. Ben-David, and G. Rahav Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia J Infect Dis 199 2009 619 624
3. S.N. Leonard, and M.J. Rybak Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious Gram-positive infections Pharmacotherapy 28 2008 458 468 (Pubitemid 351466458)
4. S.N. Leonard, C. Vidaillac, and M.J. Rybak Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations Antimicrob Agents Chemother 53 2009 2928 2933
5. K.D. Leuthner, C.M. Cheung, and M.J. Rybak Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus J Antimicrob Chemother 58 2006 338 343 (Pubitemid 44294945)
6. C. Lamer, V. de Beco, P. Soler, S. Calvat, J.Y. Fagon, and M.C. Dombret Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients Antimicrob Agents Chemother 37 1993 281 286 (Pubitemid 23046569)
7. R.G. Wunderink, J. Rello, S.K. Cammarata, R.V. Croos-Dabrera, and M.H. Kollef Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia Chest 124 2003 1789 1797 (Pubitemid 37433574)
8. E. Rubinstein, T. Lalani, G.R. Corey, Z.A. Kanafani, E.C. Nannini, and M.G. Rocha Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens Clin Infect Dis 52 2011 31 40
9. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M07-A8. Wayne, PA: CLSI; 2008.
10. Vibativ prescribing information. http://www.astellas.us/docs/us/VIBATIV- PI-Final.pdf [accessed 22 October 2010].
11. Zyvox prescribing information. http://media.pfizer.com/files/products/ uspi-zyvox.pdf [accessed 22 October 2010].
12. M.J. Rybak, B.M. Lomaestro, J.C. Rotschafer, R.C. Moellering, W.A. Craig, and M. Billeter Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists Clin Infect Dis 49 2009 325 327
13. W.E. Rose, S.N. Leonard, K.L. Rossi, G.W. Kaatz, and M.J. Rybak Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model Antimicrob Agents Chemother 53 2009 805 807
14. B.P. Howden, J.K. Davies, P.D. Johnson, T.P. Stinear, and M.L. Grayson Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications Clin Microbiol Rev 23 2010 99 139
15. G.L. French Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin J Antimicrob Chemother 58 2006 1107 1117 (Pubitemid 44884127)
16. R.W. Finberg, R.C. Moellering, F.P. Tally, W.A. Craig, G.A. Pankey, and E.P. Dellinger The importance of bactericidal drugs: future directions in infectious disease Clin Infect Dis 39 2004 1314 1320 (Pubitemid 39458517)